The novel adenosine A 2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 3, 2012, Pages 498-505

  Collins, Lyndsey E ^a,c   Sager, Thomas N ^b   Sams, Anette G ^b   Pennarola, Adam ^a   Port, Russell G ^a   Shahriari, Mona ^a   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b H LUNDBECK A S   (Denmark)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Catalepsy; Drug induced parkinsonism; Effort related decision making; Locomotion; Parkinson's disease; Tremor

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; HALOPERIDOL; LU AA47070; PIMOZIDE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ORGANOPHOSPHATE; PHOSPHORIC ACID MONO (2 (4 (3,3 DIMETHYLBUTYRYLAMINO) 3,5 DIFLUOROBENZOYLIMINO)THIAZOL 3 YLMETHYL) ESTER; PHOSPHORIC ACID MONO-(2-(4-(3,3-DIMETHYLBUTYRYLAMINO)-3,5-DIFLUOROBENZOYLIMINO)THIAZOL-3-YLMETHYL) ESTER; PRODRUG; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DECISION MAKING; DOPAMINE RECEPTOR BLOCKING; LOCOMOTION; MALE; MOTIVATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; TREMOR; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DYSKINESIA; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZATION; SPRAGUE DAWLEY RAT; TOXICITY AND INTOXICATION;

PARKINSONIA; RODENTIA;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CHOICE BEHAVIOR; DEPRESSION; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MOLECULAR TARGETED THERAPY; NEUROTOXICITY SYNDROMES; PARKINSONIAN DISORDERS; PHOSPHORIC ACID ESTERS; PIMOZIDE; PRODRUGS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; THIAZOLES; TREMOR;

EID: 80855123923     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.10.015     Document Type: Article

References (114)

1. S. Aoyama, H. Kase, and E. Borrelli Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist J Neurosci 20 2000 5848 5852 (Pubitemid 30636915)
2. W. Bara-Jimenez, A. Sherzai, T. Dimitrova, A. Favit, F. Bibbiani, and M. Gillespie Adenosine A(2A) receptor antagonist treatment of Parkinson's disease Neurology 61 2003 293 296 (Pubitemid 36975954)
3. M.E. Bardgett, M. Depenbrock, N. Downs, M. Points, and L. Green Dopamine modulates effort- based decision making in rats Behav Neurosci 123 2009 463 467
4. A.J. Betz, P.J. McLaughlin, M. Burgos, S.M. Weber, and J.D. Salamone The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors Psychopharmacology 194 2007 347 359 (Pubitemid 47389345)
5. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide Neuroscience 163 2009 97 108
6. M. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nat Neurosci Rev 3 2002 574 579 (Pubitemid 135706667)
7. J.F. Chen, R. Moratalla, F. Impagnatiello, D.K. Grandy, B. Cuellar, and M. Rubinstein The role of the D2 dopamine receptor (D2R) in A2a adenenosine-receptor (A2aR) mediated behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice Proc Natl Acad Sci 98 2001 1970 1975 (Pubitemid 32165607)
8. L.E. Collins, D.J. Galtieri, P. Collins, S.K. Jones, R.G. Port, and N.E. Paul Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity Behav Brain Res 211 2010 148 155
9. L.E. Collins, D.J. Galtieri, L.T. Brennum, T.N. Sager, J. Hockemeyer, and C.E. Muller Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH 58261, but not the adenosine A1 antagonist DPCPX Pharmacol Biochem Behav 94 2010 561 569
10. L.E. Collins, N.E. Paul, S.F. Abbas, C.E. Leser, S.J. Podurgiel, and D.J. Galtieri Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease Pharmacol Biochem Behav 99 2011 414 422
11. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism Behav Brain Res 148 2004 47 54 (Pubitemid 37543655)
12. M. Correa, M. Pardo, J. Hockemeyer, C.E. Müller, and J.D. Salamone Dopamine D2 antagonism increases selection of less effortful food-seeking behavior in a T-maze procedure in mice: reversal of the motivational impairment with adenosine antagonists Neuroscience Meeting Planner Program Number 285.6 2009 Society for Neuroscience Chicago, IL Online
13. M.S. Cousins, W. Wei, and J.D. Salamone Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs Psychopharmacology 116 1994 529 537 (Pubitemid 24374258)
14. M.S. Cousins, A. Atherton, L. Turner, and J.D. Salamone Nucleus accumbens dopamine depletions alter relative response allocation in a T-maze cost/benefit task Behav Brain Res 74 1996 189 197 (Pubitemid 26060036)
15. M.S. Cousins, D.L. Carriero, and J.D. Salamone Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs Eur J Pharmacol 322 1997 137 145 (Pubitemid 27122886)
16. M.S. Cousins, A. Atherton, and J.D. Salamone Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements Physiol Behav 64 1998 153 158 (Pubitemid 28313589)
17. F. Denk, M.E. Walton, K.A. Jennings, T. Sharp, M.F. Rushworth, and D.M. Bannerman Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort Psychopharmacology 179 2005 587 596 (Pubitemid 40674759)
18. M. El Yacoubi, J. Costentin, and J.M. Vaugeois Adenosine A2A receptors and depression Neurology 61 2003 S82 S87
19. S. Factor, M.H. Mark, R. Watts, L. Struck, A. Mori, and R. Ballerini A long-term study of istradefylline in subjects with fluctuating Parkinson's disease Parkinsonism Relat Disord 16 2010 423 426
20. A.M. Farrar, M. Pereira, F. Velasco, J. Hockemeyer, C.E. Muller, and J.D. Salamone Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing Psychopharmacology 191 2007 579 586 (Pubitemid 46355890)
21. A.M. Farrar, K.N. Segovia, P.A. Randall, E.J. Nunes, L.E. Collins, and C.M. Stopper Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors Neuroscience 166 2010 1056 1067
22. H.H. Fernandez, D.R. Greeley, R.M. Zweig, J. Wojcieszek, A. Mori, and N.M. Sussman Istradefylline as monotherapy for Parkinson's disease: results of the 6002-US-051 trial Parkinsonism Relat Disord 16 2010 16 20
23. S. Ferré, B.B. Freidholm, M. Morelli, P. Popoli, and K. Fuxe Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci 20 1997 482 487 (Pubitemid 27421712)
24. S. Ferré, P. Popoli, L. Gimenez-Llort, R. Rimondini, C.E. Müller, and I. Stromberg Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease Parkinsonism Relat Disord 7 2001 235 241 (Pubitemid 32372505)
25. S. Ferré, F. Ciruela, M. Canals, D. Marcellino, J. Burgueno, and V. Casado Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders Parkinsonism Relat Disord 10 2004 265 271 (Pubitemid 38757806)
26. S. Ferré, C. Quiroz, A.S. Woods, R. Cunha, P. Popoli, and F. Ciruela An update on adenosine A2A-dopamine D2 receptor interactions: Implications for the function of G-protein coupled receptors Curr Pharm Des 14 2008 1468 1474 (Pubitemid 351997812)
27. J.S. Fink, D.R. Weaver, S.A. Rivkees, R.A. Peterfreund, A.E. Pollack, and E.M. Adler Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum Brain Res 14 1992 186 195
28. M. Finn, A. Jassen, P. Baskin, and J.D. Salamone Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions Pharmacol Biochem Behav 57 1997 243 249 (Pubitemid 27261417)
29. S.B. Floresco, and S. Ghods-Sharifi Amygdala-prefrontal cortical circuitry regulates effort-based decision making Cereb Cortex 17 2007 251 260 (Pubitemid 46052764)
30. S.B. Floresco, M.T. Tse, and S. Ghods-Sharifi Dopaminergic and glutamatergic regulation of effort- and delay-based decision making Neuropsychopharmacology 33 2008 1966 1979 (Pubitemid 351832587)
31. L. Font, S. Mingote, A.M. Farrar, M. Pereira, L. Worden, and C. Stopper Intra- accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats Psychopharmacology (Berl) 199 2008 515 526
32. K. Fuxe, L.F. Agnati, K. Jacobsen, J. Hillion, M. Canals, and M. Torvinen Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease Neurology 61 2003 S19 S23 (Pubitemid 37505541)
33. K. Fuxe, S. Ferré, S. Genedani, R. Franco, and L.F. Agnati Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function Physiol Behav 92 2007 210 217 (Pubitemid 47381380)
34. R.J. Gillespie, S.J. Bamford, R. Botting, M. Comer, S. Denny, and S. Gaur Antagonist of the human A(2A) receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d] pyrimidines J Med Chem 52 2009 33 47
35. T.C. Hanff, S.J. Furst, and T.R. Minor Biochemical and anatomical substrates of depression and sickness behavior Isr J Psychiatry Relat Sci 47 2010 64 71
36. W. Hauber Involvement of basal ganglia transmitter systems in movement initiation Prog Neurobiol 56 1998 507 540 (Pubitemid 28407570)
37. W. Hauber, P. Neuscheler, J. Nagel, and C.E. Müller Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2a receptors in the caudate putamen of rats Eur J Neurosci 14 2001 1287 1293 (Pubitemid 35463735)
38. R.A. Hauser, J.P. Hubble, and D.D. Truong Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD Neurology 61 2003 297 303 (Pubitemid 36975955)
39. R.A. Hauser, L.M. Shulman, J.M. Trugman, J.W. Roberts, A. Mori, and R. Ballerini Istradefylline US-6002-US-013 Study Group. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations Mov Disord 23 2008 2177 2185
40. J. Hillion, M. Canals, M. Torvinen, V. Casado, R. Scott, and A. Terasmaa Coaggregation, cointernaliztion, and codesensitization of adenosine A2A receptors and dopamine D2 receptors J Biol Chem 277 2002 18091 18097 (Pubitemid 34967623)
41. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, and S. Fredduzzi Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression J Pharmacol Exp Ther 330 2009 294 303
42. K. Ishiwari, A. Betz, S. Weber, J. Felsted, and J.D. Salamone Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats Pharmacol Biochem Behav 80 2005 351 362 (Pubitemid 40170431)
43. 2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats Behav Brain Res 178 2007 190 199 (Pubitemid 46341436)
44. P. Jenner Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease Exp Opin Investig Drugs 14 2005 729 738 (Pubitemid 40895197)
45. G.A. Jicha, and J.D. Salamone Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms J Neurosci 11 1991 3822 3829
46. T. Kanda, S. Shiozaki, J. Shimada, K. Suzuki, and J. Nakamura KF17837: A novel selective adenosine A2A receptor antagonist with anticataleptic activity Eur J Pharmacol 256 1994 263 268 (Pubitemid 24134887)
47. G. Keppel Design and analysis: a researcher's handbook 1991 Prentice Hall
48. W. Knebel, N. Rao, T. Uchimura, A. Mori, J. Fisher, and M.R. Gastonguay Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease J Clin Pharmacol 51 2010 40 52
49. M. Koch, A. Schmid, and H.U. Schnitzler Role of nucleus accumbens dopamine D1 and D2 receptors in instrumental and Pavlovian paradigms of conditioned reward Psychopharmacology 152 2000 67 73
50. P.A. LeWitt, M. Guttman, J.W. Tetrud, P.J. Tuite, A. Mori, and P. Chaikin Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann Neurol 63 2008 295 302 (Pubitemid 351499859)
51. J. Mally, and T.W. Stone Potential role of adenosine antagonist therapy in pathological tremor disorders Pharmacol Ther 72 1996 243 250 (Pubitemid 26425812)
52. J. Mally, and T.W. Stone Potential of adenosine A2A antagonists in the treatment of movement disorders CNS Drugs 10 1998 311 320 (Pubitemid 28543729)
53. S. Mingote, L. Font, A.M. Farrar, R. Vontell, L.T. Worden, and C.M. Stopper Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway J Neurosci 28 2008 9037 9046
54. H. Miwa Rodent models of tremor Cerebellum 6 2007 66 72 (Pubitemid 46410668)
55. H. Miwa, K. Hama, Y. Kajimoto, and T. Kondo Effects of zonisamide on experimental tremors in rats Parkinsonism Relat Disord 14 2008 33 36
56. H. Miwa, T. Kubo, A. Suzuki, and T. Kondo Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect Parkinsonism Relat Disord 15 2009 30 35
57. Y. Mizuno, K. Hasegawa, T. Kondo, S. Kuno, M. Yamamoto, and Japanese Istradefylline Study Group Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study Mov Disord 25 2010 1437 1443
58. 2A receptors as a basis for the treatment of Parkinson's disease Neurol Sci 22 2002 71 72
59. A.M. Mott, E.J. Nunes, L.E. Collins, R.G. Port, K.S. Sink, and J. Hockemeyer The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure Psychopharmacology 204 2009 103 112
60. K.L. Nowend, M. Arizzi, B.B. Carlson, and J.D. Salamone D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption Pharmacol Biochem Behav 69 2001 373 382 (Pubitemid 32758720)
61. E.J. Nunes, P.A. Randall, J.L. Santerre, A.B. Given, T.N. Sager, and M. Correa Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonist Neuroscience 170 2010 268 280
62. 2A antagonist KW-6002 on motor and motivational processes in the rat Psychopharmacology 184 2006 46 55 (Pubitemid 43005756)
63. M. Pardo, L. Lopez-Cruz, J. Hockemeyer, C.E. Muller, J.D. Salamone, and M. Correa Interaction between dopamine D2 receptors and adenosine A1 and A2A receptors: studies of c-Fos immunoreactivity, behavioral activation, and effort related decision making Neuroscience Meeting Planner Program Number 916.19 2010 Society for Neuroscience San Diego, CA Online
64. A. Pinna Novel investigational adenosine A2A receptor antagonist for Parkinson's disease Expert Opin Investig Drugs 18 2009 1619 1631
65. A. Pinna, J. Wardas, N. Simola, and M. Morelli New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists Life Sci 77 2005 3259 3267 (Pubitemid 41434071)
66. M. Rodriguez Diaz, P. Abdala, P. Barroso-Chinea, J. Obeso, and T. Gonzalez-Hernandez Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease Behav Brain Res 122 2001 79 92 (Pubitemid 32238177)
67. D.L. Rosin, A. Robeva, R.L. Woodard, P.G. Guyenet, and J. Linden Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system J Comp Neurol 401 1998 163 186 (Pubitemid 28481960)
68. J.D. Salamone Dopaminergic involvement in activational aspects of motivation: effects of haloperidol on schedule induced activity, feeding and foraging in rats Psychobiology 16 1988 196 206
69. J.D. Salamone Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes Psychopharmacology 107 1992 160 174
70. J.D. Salamone Preladenant, an adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders IDrugs 13 2010 723 731
71. J.D. Salamone Involvement of nucleus accumbens dopamine in behavioral activation and effort- related function L.L. Iversen, S.D. Iversen, S.B. Dunnett, A. Bjorklund, Dopamine handbook 2010 Oxford University Press Oxford 286 300
72. J. Salamone, and P. Baskin Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor Pharmacol Biochem Behav 53 1996 179 183 (Pubitemid 26117741)
73. J.D. Salamone, and M. Correa Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine Behav Brain Res 137 2002 3 25 (Pubitemid 35346426)
74. J.D. Salamone, and M. Correa Dopamine/adenosine interactions involved in effort-related aspects of food motivation Appetite 53 2009 422 425
75. J.D. Salamone, C.J. Johnson, L.D. McCullough, and R.E. Steinpreis Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat Psychopharmacology 102 1990 529 534 (Pubitemid 20379510)
76. J.D. Salamone, R.E. Steinpreis, L.D. McCullough, P. Smith, D. Grebel, and K. Mahan Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure Psychopharmacology (Berl) 104 1991 515 521
77. J.D. Salamone, K. Mahan, and S. Rogers Ventrolateral striatal dopamine depletions impair feeding and food handling in rats Pharmacol Biochem Behav 44 1993 605 610
78. J.D. Salamone, M.S. Cousins, and S. Bucher Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure Behav Brain Res 65 1994 221 229
79. J.D. Salamone, M.S. Cousins, C. Maio, M. Champion, T. Turski, and J. Kovach Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure Psychopharmacology (Berl) 125 1996 105 112 (Pubitemid 26172087)
80. J.D. Salamone, A.J. Mayorga, J.T. Trevitt, M.S. Cousins, A. Conlan, and A. Nawab Tremulous jaw movements in rats: a model of parkinsonian tremor Prog Neurobiol 56 1998 591 611 (Pubitemid 29012460)
81. J. Salamone, M. Correa, B. Carlson, A. Wisniecki, A. Mayorga, and E. Nisenbaum Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism Life Sci 68 2001 2579 2584 (Pubitemid 32455697)
82. J.D. Salamone, M.N. Arizzi, M.D. Sandoval, K.M. Cervone, and J.E. Aberman Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task Psychopharmacology (Berl) 160 2002 371 380
83. J.D. Salamone, M. Correa, S. Mingote, and S.M. Weber Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse J Pharmacol Exp Ther 305 2003 1 8 (Pubitemid 36373829)
84. J.D. Salamone, B.B. Carlson, C. Rios, E. Lentini, M. Correa, and A. Wisniecki Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243 Behav Brain Res 156 2005 173 179 (Pubitemid 39576057)
85. J.D. Salamone, M. Correa, S.M. Mingote, and S.M. Weber Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine Curr Opin Pharmacol 5 2005 34 41 (Pubitemid 40124532)
86. J.D. Salamone, M. Correa, S.M. Mingote, S.M. Weber, and A.M. Farrar Nucleus accumbens dopamine and the forebrain circuitry involved in behavioral activation and effort-related decision making: implications for understanding anergia and psychomotor slowing in depression Curr Psychiatry Rev 2 2006 267 280 (Pubitemid 44027882)
87. J.D. Salamone, M. Correa, A. Farrar, and S.M. Mingote Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits Psychopharmacology (Berl) 191 2007 461 482 (Pubitemid 46355902)
88. J.D. Salamone, A.J. Betz, K. Ishiwari, J. Felsted, L. Madson, and B. Mirante Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism Front Biosci 13 2008 3594 3605 (Pubitemid 351606098)
89. J.D. Salamone, K. Ishiwari, A.J. Betz, A.M. Farrar, S.M. Mingote, and L. Font Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism Parkinsonism Relat Disord 14 2008 S130 S134
90. J.D. Salamone, A.M. Farrar, L. Font, V. Patel, D.E. Schlar, and E.J. Nunes Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism Behav Brain Res 201 2009 216 222
91. J.D. Salamone, M. Correa, A.M. Farrar, E.J. Nunes, and M. Pardo Dopamine, behavioral economics, and effort Front Behav Neurosci 3 2009 13
92. J.D. Salamone, M. Correa, A.M. Farrar, E.J. Nunes, and L.E. Collins The role of dopamine/adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation Future Neurol 5 2010 377 392
93. A.G. Sams, G.K. Mikkelsen, M. Larsen, M. Langgard, M.E. Howells, and T.J. Schroder Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl- butyrylamino)-3,5-difluoro- benzoylimino]thiazol-3-ylmethyl} ester (LuAA47070): a phosphonooxymethylene prodrug of a potent and selective hA2A receptor antagonist J Med Chem 54 2011 751 764
94. S.N. Schiffman, O. Jacobs, and J.J. Vanderhaeghen The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in-situ hybridization study J Neurochem 57 1991 1062 1067
95. M.A. Schwarzschild, J.F. Chen, and A. Ascherio Caffeinated clues and the promise of adenosine A(2A) antagonists in PD Neurology 58 2002 1154 1160 (Pubitemid 34411857)
96. S. Shiozaki, S. Ichikawa, J. Nakamura, S. Kitamura, K. Yamada, and Y. Kuwana Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP Psychopharmacology 147 1999 90 95 (Pubitemid 30010028)
97. N. Simola, S. Fenu, P.G. Baraldi, M.A. Tabrizi, and M. Morelli Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions Exp Neurol 189 2004 182 188 (Pubitemid 39024467)
98. N. Simola, S. Fenu, P.G. Baraldi, M.A. Tabrizi, and M. Morelli Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease J Neurol Sci 248 2006 48 52 (Pubitemid 44647312)
99. K.S. Sink, V.K. Vemuri, T. Olszewska, A. Makriyannis, and J.D. Salamone Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior Psychopharmacology 196 2008 565 574
100. M. Stacy, D. Silver, T. Mendis, J. Sutton, A. Mori, and P. Chaikin A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease Neurology 70 2008 2233 2240
101. I. Stromberg, P. Popoli, C.E. Muller, S. Ferre, and K. Fuxe Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in dopamine-denervated striatum Eur J Neurosci 12 2000 4033 4037
102. P. Svenningsson, C. Le Moine, G. Fisone, and B.B. Fredholm Distribution, biochemistry and function of striatal adenosine A2A receptors Prog Neurobiol 59 1999 355 396 (Pubitemid 29352341)
103. R.N. Takahashi, F.A. Pamplona, and R.D. Prediger Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies Front Biosci 13 2008 2614 2632 (Pubitemid 351599708)
104. M.T. Treadway, and D.H. Zald Reconsidering anhedonia in depression: lessions from translational neuroscience Neurosci Biobehav Rev 35 2011 537 555
105. J. Trevitt, C. Vallance, A. Harris, and T. Goode Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease Pharmacol Biochem Behav 92 2009 521 527
106. J. Trevitt, K. Kawa, A. Jalali, and C. Larsen Differential effects of adenosine antagonists in two models of parkinsonian tremor Pharmacol Biochem Behav 94 2009 24 29
107. E. Tronci, N. Simola, F. Borsini, N. Schintu, L. Frau, and P. Carminati Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats Eur J Pharmacol 566 2007 94 102 (Pubitemid 46782796)
108. 2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model Pharmacol Biochem Behav 90 2008 540 544
109. R. Vontell, K.N. Segovia, A.J. Betz, S. Mingote, K. Goldring, R.W. Cartun, and J.D. Salamone Immunocytochemistry studies of basal ganglia adenosine A2A receptors in rat and human tissue J Histotech 33 2010 41 47
110. M.E. Walton, D.M. Bannerman, and M.F. Rushworth The role of rat medial frontal cortex in effort- based decision making J Neurosci 22 2002 10996 11003 (Pubitemid 36005176)
111. M.E. Walton, D.M. Bannerman, K. Alterescu, and M.F. Rushworth Functional specialization within medial frontal cortex of the anterior cingulate for evaluating effort-related decisions J Neurosci 23 2003 6475 6479 (Pubitemid 36909873)
112. W.F. Wang, K. Ishiwata, H. Nonaka, S. Ishii, M. Kiyosawa, and J. Shimada Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography Nucl Med Biol 27 2000 541 546
113. J. Wardas, J. Konieczny, and E. Lorenc-Koci SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats Synapse 41 2001 160 171
114. L.T. Worden, M. Shahriari, A.M. Farrar, K.S. Sink, J. Hockemeyer, and C.E. Muller The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists Psychopharmacology (Berl) 203 2009 489 499